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Objective: To elucidate the anxiolytic and free radical scavenging effect of methanolic
extract of Apium graveolens (A. graveolens) in adult C57BL/6 mice.
Methods: Sixty male mice were divided into 6 groups: control, vehicle, positive control
and A. graveolens (125, 250 and 500 mg/kg). Different behavioral models of elevated
plus maze, open ﬁeld, light/dark, hole-board and pentobarbital-induced sleep were used to
assess anxiety-like behavior. Biochemical parameters including monoamine oxidase-A
(MAO-A) activity, lipid peroxidation, % inhibition of superoxide anion and glutathione
peroxidase activity were measured. Histologic studies were also examined.
Results: Mice receiving various doses of A. graveolens (125, 250 and 500 mg/kg)
showed an alleviation of anxiety-like behavior as evidenced by the battery of behavioral
tests. Likewise, A. graveolens treatment was found to signiﬁcantly decrease MAO-A
activity, lipid peroxidation as well as cause a signiﬁcant increase of % inhibition of su-
peroxide anion and glutathione peroxidase activity in both cortex and striatum. The total
number of survival neurons found in the frontal cortex and striatum was signiﬁcantly
higher than that of the vehicle-treated group.
Conclusions: Taken together, we showed that A. graveolens improve the behavioral
changes which might be related to the inhibition of free radicals and modulation of MAO-
A activity resulting in an increased number of survival neurons. Our ﬁndings suggest the
therapeutic potential of A. graveolens in the treatment of anxiety.1. Introduction
Anxiety is one of themost common neuropsychiatric disorders.
It is divided into generalized anxiety disorder, panic disorder, post-traumatic stress disorder, social phobias and agoraphobia which
contribute to impairing their quality of life and increasing costs of
general medical inpatients [1]. It is common in all age groups and
characterized by persistent worry occurring over at least six
months associated with mental and somatic symptoms including
arousal, irritability, fatigue and sleep disturbance [2,3].
Benzodiazepine anxiolytics are the ﬁrst line of prescription to
patients with anxiety. The adverse effects of benzodiazepine
usage have been reported including anterograde amnesia,
physical dependence, cognitive dysfunction, risk of cancer and
risk of falling especially in the elderly [4–6]. Therefore, alternative
medicines have drawn an attention in the search for medicinal
plants with potent biological activity.
Apium graveolens Linn. (A. graveolens) is an annual herb
belonging to family Apiaceae with green blanched leaf stalks. It
is found in North and South Americas, Southern Europe, Africacle under the CC BY-NC-ND license (http://
Supita Tanasawet et al./Asian Pac J Trop Biomed 2017; 7(1): 20–26 21and Asia. Its major active constituents are L-3-n-butylphthalide,
sedanolide, linoleic acid, ﬂavonoids, phenolic compounds and
volatile oil, which are extracted from its various part including
roots, leaves and seeds [7–9]. Several studies have reported its
pharmacological activity on antimicrobial, anti-inﬂammatory,
anti-arthritis, antiulcerogenic, antihyperlipidemia and anti-
hypertension [8–11]. Concerning the beneﬁcial effect on the
central nervous system, a pure compound extracted from
A. graveolens (L-3-n-butylphthalide) was demonstrated to
improve cognitive impairment in the Alzheimer's mouse model
[7]. Its synthesized compound, DL-3-n-butylphthalide, has shown
neuroprotective effects on cerebral ischemia and 1-methyl-4-
phenylpyridinium ion-induced Parkinson's disease [12,13].
Thus, the present study aimed to elucidate the potential anxio-
lytic effect ofA. graveolens in adult C57BL/6mice, and to examine
its effect on free radical scavenging and histological alterations.
2. Materials and methods
2.1. Preparation of plant extracts
Whole plant materials of A. graveolens were purchased from
Lampang Herb Conservation, Thailand. A. graveolens was
identiﬁed by a botanist and a voucher specimen (BKF: 188856)
was deposited at the Forest Herbarium, Bangkok, Thailand. Dried
plants were ground into powder and macerated in 70% methanol
at 1:10 (w/v) ratio for 72 h. Thereafter, it was ﬁltered through a
satin cloth followed by Whatman No. 1 ﬁlter paper to achieve the
ﬁltrate methanolic extract. The residue was then re-extracted
twice following the same procedure. The combined methanolic
extract was evaporated to dryness by using a rotary evaporator
under vacuum (Rotavapor R-300, BU¨CHI, Switzerland) at 50 C
and ﬁnally lyophilized to achieve a powder. The yield of meth-
anolic A. graveolens extract was found to be 15.88% (w/w).
A. graveolens was administered p.o. in distilled water once daily.
2.2. Drugs and chemicals
Diazepam (2 mg/tablet) (Government Pharmaceutical Orga-
nization, Bangkok, Thailand) was used as a positive control for
anxiolytic effect. The drug was dissolved in distilled water and
administered orally. Sodium pentobarbital was purchased from
Sigma Chemical Company (St. Louis, MO, USA). All other
chemicals and reagents used in this study were of analytical grade.
2.3. Laboratory animals
Two-month-old adult C57BL/6 mice weighing between 30 and
35 g (n = 10) were obtained from the National Laboratory Animal
Center, Mahidol University, Bangkok, Thailand. The animals were
housed ﬁve per cage and maintained under standard environmental
conditions (12 h light–dark cycle, 23–27 C temperature, 50% hu-
midity).Micewere fedwith standard food andwater ad libitum. The
study was approved by the Institutional Animal Care and Use
Committee andwas carried out in accordancewith the Principles for
the Care and Use of Research Animals outlined by Faculty of Sci-
ence, Prince of Songkla University, Thailand (MOE0521.11/582).
2.4. Experimental design
The adult male C57BL/6 mice were divided into 6 groups of
ten mice each to receive the daily treatments: (1) no treatment(naive control), (2) distilled water as vehicle control, (3) 2.0 mg/
kg body weight diazepam as positive control, (4) 125 mg/kg
body weight A. graveolens, (5) 250 mg/kg body weight
A. graveolens and (6) 500 mg/kg body weight A. graveolens.
Treatments were administered once daily for 4 weeks. The
behavioral tests were determined on Day 1, 7, 14, 21 and 28
after 1 h of A. graveolens, distilled water or standard drug
administration, whereas biochemical assay and histological ex-
amination were performed at the end of the experiment.
2.5. Behavioral tests
2.5.1. Elevated plus maze (EPM) test
EPM apparatus (two open arms and two closed arms elevated
50 cm off the ﬂoor) was employed to measure the anxiety
behavior of the experimental animals. The mice were placed at
the center of the plus maze facing one of the open arms. During
the 5-min test period, the time spent in the open arm was
recorded. Behavioral testing of all animals was conducted every
7 days by observers blind to the treatment group.
2.5.2. Open ﬁeld test
Open ﬁeld test was used to evaluate the anxiety-related
behavior of the mice. The apparatus consisted of a plexiglass
box (height: 38.0 cm; length: 90.0 cm; width: 90.0 cm) divided
into 25 squares. One hour after oral administration of
A. graveolens (125, 250, 500 mg/kg body weight) or standard
drug, each mouse was centrally placed in the arena and the
behavioral patterns were investigated for 5 min.
2.5.3. Light/dark test
The test apparatus consisted of two equal size compartments
by a dark safe compartment and a large illuminated compartment.
The experiment was initiated by placing a mouse into the center
of the illuminated box facing the hole and the mouse was allowed
to freely explore the apparatus for 5 min. Time spent in light and
dark box was then recorded with the aid of a video camera.
2.5.4. Hole-board test
The hole-board apparatus consisted of a plexiglass box
(height: 50.0 cm; length: 40.0 cm; width: 40.0 cm) with 16
evenly distributed holes (diameter 2.0 cm) was elevated 25 cm
from the ﬂoor. Mice were then placed in the center of apparatus
and allowed to freely move for 5 min. The number of head dips
was evaluated.
2.5.5. Pentobarbital-induced sleep time test
Sixty minutes after administration of A. graveolens, diazepam
or distilledwater, themicewere injectedwith sodium pentobarbital
(50 mg/kg body weight, i.p.) to induce sleep. The duration of time
between the pentobarbital administration and loss of righting reﬂex
was considered as the sleep latency (min) and the duration of time
between loss of righting reﬂex and voluntary recovery of righting
reﬂex was considered as sleeping time (min).
2.6. Biochemical analysis
2.6.1. Assay for monoamine oxidase (MAO)-A activity
Animals were anesthetized with i.p. injection of pentobarbital
sodium at a dose of 50 mg/kg body weight after the completion of
the behavioral tests. Brains (cortex and striatum) were dissected
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Figure 2. Effects of A. graveolens (A125, 250 and 500 mg/kg, i.p.),
diazepam (DZ 2 mg/kg, i.p.), vehicle (V) or control (C) on the time of
central area approach in the open ﬁeld test in mice.
Data are presented as mean ± SD, n = 10 each group; #: P < 0.05 positive
control versus vehicle, *: P < 0.05 A. graveolens versus vehicle.
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Figure 1. Effects of A. graveolens (A125, 250 and 500 mg/kg, i.p.),
diazepam (DZ 2 mg/kg, i.p.), vehicle (V) or control (C) on the time spent in
the open arms during EPM test in mice.
Data are presented as mean ± SD, n = 10 each group. #: P < 0.05 positive
control versus vehicle, *: P < 0.05 A. graveolens versus vehicle.
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buffer, pH 7.4 with glass Potter-Elvehjem homogenizer. The ho-
mogenates were incubated with 500 mmol/L tyramine plus
500 nmol/L pargyline in order to inhibit MAO-B activity. The
chromogenic solution prepared in the assay contained vanillic acid
(1 mmol/L), 4-aminoantipyrine (500 mmol/L) and horse radish
peroxidase (4 IU/mL) in potassium phosphate buffer (0.2 mol/L,
pH 7.6). The absorbance was measured spectrophotometrically at
490 nm. The MAO-A activity was then determined and expressed
as mmol/min g tissue.
2.6.2. Assay for lipid peroxidation
Malondialdehyde (MDA) which is the most abundant product
from lipid peroxidation was evaluated by the reaction
of thiobarbituric acid and homogenized brain samples (cortex and
striatum). Afterwards, the mixtures were heated at 100 C for
60 min and cooled under tap water. After centrifugation at 4000 r/
min for 10 min, the organic layer was separated and the optical
density (OD) was measured at 532 nm using a spectrophotometer.
The concentration of MDA was expressed as nmol/mg protein.
2.6.3. Assay for % inhibition of superoxide anion ðO2 − Þ
The O2 − assay was conducted according to xanthine/
xanthine oxidase system which converted nitro blue tetrazolium
to formazan. The reagent mixture (ethylenediaminetetraacetic
acid, nitro blue tetrazolium, xanthine and xanthine oxidase) was
incubated with homogenized brain samples (cortex and striatum)
and the OD was measured at 560 nm in comparison to standard
curve of tempol. The data were expressed as % inhibition
calculated based on the following formula:
%Inhibition = ½ðODof reagent−ODof sampleÞ=ODof reagent×100
2.6.4. Assay for glutathione peroxidase (GPx) activity
Supernatant from the brain tissue (cortex and striatum) was
incubated with the reaction mixture containing 48 mmol/L sodium
phosphate, 0.38mmol/Lethylenediaminetetraacetic acid, 0.12mmol/
L b-nicotinamide adenine dinucleotide phosphate, 0.95 mmol/L so-
dium azide, 3.2 units of glutathione reductase, 1mmol/L glutathione,
0.02 mmol/L DL-dithiothreitol and 0.000 7% H2O2 in comparison to
the standard enzyme GPx solution. The disappearance of nicotin-
amide adenine dinucleotide phosphate was measured at 340 nm,
25 C, and the data were expressed as units/g protein.
2.7. Cresyl violet staining
Frontal cortex and striatum from various groups of treatment
were sectioned and stained with 0.5% cresyl violet in order to
determine neuronal density. The sections were observed and
photographed under light microscopy (E600, Nikon, Japan).
2.8. Statistical analysis
Experimental data were expressed as mean ± SD. Signiﬁcant
differences were compared by ANOVA (Tukey's post hoc test).
The statistical difference was regarded as P < 0.05.
3. Results
3.1. EPM test
We observed that 2 mg/kg diazepam and A. graveolens at all
doses (125, 250, 500 mg/kg) signiﬁcantly increased the timespent in the open arms; the 125 mg/kg dose demonstrated the
highest effect (P < 0.05) (Figure 1).3.2. Open ﬁeld test
Diazepam (2 mg/kg) and A. graveolens (125, 250, 500 mg/
kg) signiﬁcantly increased the ambulation activity at the central
area (P < 0.05) with a peak effect at 125 mg/kg (Figure 2).3.3. Light/dark test
Figure 3 demonstrates a signiﬁcant increase of time spent in
the light chamber in the diazepam and A. graveolens (125, 250,
500 mg/kg) treated groups (P < 0.05).
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Figure 3. Effects of A. graveolens (A125, 250 and 500 mg/kg, i.p.),
diazepam (DZ 2 mg/kg, i.p.), vehicle (V) or control (C) on the time spent in
the light chamber during light/dark test in mice.
Data are presented as mean ± SD, n = 10 each group; #: P < 0.05 positive
control versus vehicle, *: P < 0.05 A. graveolens versus vehicle.
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The administration of A. graveolens (125, 250, 500 mg/kg)
signiﬁcantly increased the number of head dips compared to the
vehicle control. Peak effect was demonstrated at dose of 125 mg/
kg. Mice treated with standard drug (2 mg/kg diazepam)
demonstrated a signiﬁcant increase on head dips compared to
those observed in the vehicle control group (P < 0.05)
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Figure 4. Effects of A. graveolens (A125, 250 and 500 mg/kg, i.p.),
diazepam (DZ 2 mg/kg, i.p.), vehicle (V) or control (C) on number of head
dips during hole-board test in mice.
Data are presented as mean ± SD, n = 10 each group; #: P < 0.05 positive
control versus vehicle, *: P < 0.05 A. graveolens versus vehicle.
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Figure 5. Effects of A. graveolens (A125, 250 and 500 mg/kg, i.p.), diazepam
sleeping time (B) after pentobarbital-induced sleeping time test in mice.
Data are presented as means ± SD, n = 10 each group; #: P < 0.05 positive co3.5. Pentobarbital-induced sleeping time test
In vehicle-treated animals, the righting reﬂex was lost after
pentobarbital injection for 5.47 min (Figure 5A). However, the
animals who received 125, 250 and 500 mg/kg A. graveolens
and diazepam showed a signiﬁcantly decreased sleep latency
compared to the vehicle-treated group (P < 0.05). The sleeping
time (Figure 5B) was signiﬁcantly increased by A. graveolens
(125, 250 and 500 mg/kg) (P < 0.05) and 2 mg/kg diazepam
treatment (P < 0.05).
3.6. MAO-A activity
The effect of A. graveolens on brain MAO-A is shown in
Figure 6. The administration of A. graveolens (125, 250 and
500 mg/kg) markedly decreased MAO-A activity when
compared to the vehicle (P < 0.05) in the mouse speciﬁc brain
regions including cortex and striatum. Peak effect was found in
the 125 mg/kg A. graveolens treatment group.
3.7. Brain lipid peroxidation and antioxidant enzyme
activity
The cortical MDA level (Table 1) in A. graveolens-treated
group (125, 250 and 500 mg/kg) was signiﬁcantly decreased
compared with the vehicle group (P < 0.05). This effect was
parallel with that in the striatum (Table 2), which was also
characterized by a signiﬁcant decrease of MDA level in
A. graveolens (125 and 250 mg/kg) treated group compared to
the vehicle (P < 0.05). In addition, the administration of
A. graveolens extract (125 and 250 mg/kg) signiﬁcantly
increased % inhibition of O2 − both in the cortex and striatum
(P < 0.05) (Tables 1 and 2). The most important antioxidant
enzyme GPx was found to be signiﬁcantly increased at all doses
of A. graveolens treatment in the cortex and striatum (P < 0.05)
(Tables 1 and 2).
3.8. Cresyl violet staining
The administration of 250 mg/kg A. graveolens signiﬁcantly
increased neuron density in frontal cortex and 125 mg/kg
A. graveolens signiﬁcantly increased neuron density in striatum
(Figure 7).Ti
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Figure 6. Effects of A. graveolens (A125, 250 and 500 mg/kg, i.p.), diazepam (DZ 2 mg/kg, i.p.), vehicle (V) or control (C) on MAO-A activity in the
cortex (A) and striatum (B).
Data are presented as means ± SD, n = 5 each group. #: P < 0.05 positive control versus vehicle, *: P < 0.05 A. graveolens versus vehicle.
Table 2
Effects of oral administration of A. graveolens on lipid peroxidation and
antioxidant status in the striatum.
Striatum MDA
(nmol/mg protein)
O2 −
(% inhibition)
GPx
(IU/g protein)
Control 3.73 ± 0.36 12.43 ± 0.94 8.87 ± 0.68
Vehicle 3.62 ± 0.59 12.82 ± 0.71 8.54 ± 2.04
Diazepam 2.84 ± 0.58a 19.16 ± 1.06a 15.81 ± 1.22a
A. graveolens
125 mg/kg
2.93 ± 0.33a 29.68 ± 1.08a 18.37 ± 1.15a
A. graveolens
250 mg/kg
3.16 ± 0.47a 21.90 ± 0.73a 15.71 ± 1.26a
A. graveolens
500 mg/kg
3.56 ± 0.45 18.00 ± 0.83 12.10 ± 1.22a
Data are presented as mean ± SD, n = 5 each group. a: P < 0.05 positive
control or A. graveolens versus vehicle.
Table 1
Effects of oral administration of A. graveolens on lipid peroxidation and
antioxidant status in the cerebral cortex.
Cortex MDA
(nmol/mg protein)
O2 −
(% inhibition)
GPx
(IU/g protein)
Control 5.06 ± 0.62 10.93 ± 1.01 8.45 ± 0.71
Vehicle 4.82 ± 0.44 10.85 ± 1.72 9.09 ± 0.27
Diazepam 3.10 ± 0.51a 15.19 ± 0.95a 15.73 ± 0.90a
A. graveolens
125 mg/kg
3.13 ± 0.11a 20.68 ± 1.71a 16.55 ± 1.18a
A. graveolens
250 mg/kg
2.95 ± 0.41a 27.60 ± 1.29a 19.55 ± 1.18a
A. graveolens
500 mg/kg
3.35 ± 0.64a 14.77 ± 0.85 14.43 ± 1.04a
Data are presented as mean ± SD, n = 5 each group. a: P < 0.05 positive
control or A. graveolens versus vehicle.
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Anxiety is a psychophysiological and behavioral condition
characterized by an increased arousal, expectancy, neurochem-
ical activation and changes in behavioral patterns [1,2,14]. The
pathophysiology of anxiety disorder is not yet fully elucidated;
however, an involvement of neurotransmitter including g-
aminobutyric acid, serotonin and noradrenergic system in
several brain regions is evidenced [15]. In the present work, we
examined the anxiolytic effect of A. graveolens using a battery
of behavioral tests including EPM, open ﬁeld, light/dark, hole-
board, pentobarbital-induced sleeping tests comparable to diaz-
epam as a standard drug. Furthermore, biochemical alterations
and histological study were also evaluated.
The validity of the EPM behavioral test as an anxiety model
of a neuropsychiatric phenotype has been evaluated [16]. The
EPM paradigm relies on response of rodents to the open
spaces or the maze height suggesting anxiogenic stimuli.
Diazepam, a classical anxiolytic drug commonly prescribed to
target anxiety disorder, has been used in this study as a
positive control. We found that diazepam treatment had a
positive anxiolytic effect on EPM, similar to the previous
observation [17,18]. Following various doses of A. graveolens
administration (highest effect was found at dose of 125 mg/
kg), the mice demonstrated a signiﬁcantly increased time
spent in the open arms compared to the control group.
Hereafter, light/dark transition test has also been measured
based on their aversion to the bright areas. The present study
demonstrated that all doses of A. graveolens used in this
study increased time spent in light chamber particularly at the160
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then further conﬁrmed to measure head dip activity. The
decrease in number of head dip reﬂects anxiety-like behavior.
Our ﬁnding showed that A. graveolens (125–500 mg/kg, peak
effect at 125 mg/kg) increase the number of head dips. Another
test to conﬁrm anxiety-related behavior, open ﬁeld test, has been
suggested as a model of normal anxiety sensitive to the anxi-
olytic effect in rodent which provides the stress created by the
brightly lit, unprotected center and novel environment explo-
ration [16]. The anxiogenic-like behavior is indicated by the
avoidance of the central area approach while increased time
spent in central area indicates anxiolytic effect. The
A. graveolens extract, at all doses (peak effect at 125 mg/kg),
similar to diazepam, increased the time spent in the central area.
This is in good agreement with previous studies which reported
the low level of anxiety-related behaviors obtained from EPM,
light/dark, hole-board and open ﬁeld test in response to the
benzodiazepine diazepam [16,17,19]. According to our result,
A. graveolens administration provided consistent results in the
various experimental models of anxiety reinforcing its
anxiolytic effect at all doses (125–500 mg/kg); however, peak
effect was obtained at 125 mg/kg.
It has been shown that anxiety is one of the major causes of
sleep disturbance [3]. Hence, we addressed the question of
whether A. graveolens treatment attenuated sleep deprivation.
The monoaminergic system (serotonin, 5-hydroxytryptamine)
plays an important role in anxiety and control of sleep-wake
behavior [20,21]. Our study demonstrated that A. graveolens
prolonged sleep time and decreased sleep latency as shown in
pentobarbital-induced sleeping time test, consistent with the
reduction in the activity of MAO-A, which is the major enzyme
oxidizing serotonin and may potentiate anxiety treatment. We
found that treatment with A. graveolens preferentially inhibited
MAO-A and speculated that a consequent increase in synaptic
serotonin concentration reduced the anxiety-like behavior.
Recent evidence has indicated a close interrelation between
anxiety disorder and oxidative stress in both human and animal
which may play a major role in anxiety-related behavior [22,23].
The brain tissue is high susceptible to oxidative damage for
several reasons, including (i) its high oxygen consumption, thus
producing large amounts of oxygen-free radical and reactive-
oxygen substrates, (ii) its rich content of radical sensitive poly-
unsaturated fatty acids constituting the neuronal membranes
which are ready for oxidation, and (iii) its neurotoxic metabolites
effects from auto-oxidation of neurotransmitters [24]. The
imbalance between reactive-oxygen species (e.g. O2 − , hydrogen
peroxide) overproduction and reduction of intracellular
antioxidative protection (e.g. GPx, superoxide dismutase,
catalase) results in damage to cell structures (lipids, proteins,
and DNA) which are oxidized, hence causing cellular
dysfunction and ultimately neuronal cell death. Our study
indicated that A. graveolens treatment can signiﬁcantly decrease
the end product of lipid peroxidation MDA, increase the level of
enzymatic GPx activity and % inhibition of O2 − in the cortex
and striatum of homogenated brain tissue. Ultimately, neuronal
survival was shown to be increased in the brain.
Flavonoids, major bioactive compounds present in celery,
have been reported on the antioxidation function via radical
scavenging capacity on MDA and enhanced the activities of su-
peroxide dismutase and GPx [25–27]. Therefore, it could be
suggested the anxiolytic potential of A. graveolens possibly
acting via the antioxidant defense mechanism and preferentiallymodulating the brain serotoninergic system speciﬁcally in the
cortex and striatum.
Taken together, we have demonstrated the action of
A. graveolens extract with maximal effect at 125 mg/kg body
weight on anxiety and might be beneﬁcial for the establishment
in the clinical use of A. graveolens in patients with anxiety
disorder. However, its active constituents and precise mode of
actions need to be further investigated.Conﬂict of interest statement
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